Table 2 Liver function-related parameters and serum lipid levels before and 12 weeks after consuming FRVE
Group (total = 52) | |||||||
|---|---|---|---|---|---|---|---|
Control (n = 25) | FRVE (n = 27) | ||||||
0 weeks | 12 weeks | pa | 0 weeks | 12 weeks | pa | pb | |
AST (IU/L)* | 20.48 (± 1.44) | 19.88 (± 1.24) | 0.778 | 20.15 (± 1.12) | 20.85 (±1.75) | 0.836 | |
△ change | −0.60 (± 1.38) | 0.70 (±0.96) | 0.436 | ||||
ALT (IU/L)* | 17.67 (± 2.71) | 17.25 (± 1.96) | 0.500 | 16.63 (± 1.62) | 16.89 (±1.90) | 0.928 | |
△ change | −0.42 (± 1.88) | 0.26 (±1.31) | 0.765 | ||||
AST/ALT ratio | 1.44 (± 0.10) | 1.36 (± 0.10) | 0.095 | 1.40 (± 0.09) | 1.38 (±0.08) | 0.832 | |
△ change | −0.09 (± 0.05) | −0.02 (±0.09) | 0.523 | ||||
GGT (mg/dL)* | 18.32 (± 2.02) | 17.48 (± 1.99) | 0.241 | 21.59 (± 3.06) | 19.44 (±2.88) | 0.063 | |
△ change | −0.84 (± 0.70) | −2.15 (±1.11) | 0.331 | ||||
ALP (IU/L) | 64.56 (± 2.92) | 63.08 (± 2.50) | 0.289 | 66.00 (± 4.21) | 65.31 (±4.28) | 0.608 | |
△ change | −1.48 (± 1.36) | −0.63 (±1.21) | 0.642 | ||||
TC (mg/dL) | 190.84 (± 5.07) | 187.20 (± 4.93) | 0.231 | 179.44 (± 5.69) | 176.56 (±5.89) | 0.377 | |
△ change | −3.64 (± 2.96) | −2.89 (±3.22) | 0.865 | ||||
TG (mg/dL)* | 125.76(± 23.55) | 97.68 (± 11.12) | 0.073 | 138.74 (± 22.23) | 110.70 (±17.26) | 0.046 | |
△ change | −28.08 (± 13.64) | −28.04 (±14.20) | 0.998 | ||||
HDL-C (mg/dL) | 60.44 (± 2.93) | 62.32 (± 2.44) | 0.184 | 62.59 (± 3.48) | 62.52 (±3.23) | 0.957 | |
△ change | 1.88 (± 1.38) | −0.07 (±1.37) | 0.320 | ||||
LDL-C (mg/dL) | 105.25 (± 5.39) | 105.34 (± 5.01) | 0.976 | 92.26 (± 5.61) | 95.73 (±5.71) | 0.306 | |
△ change | 0.10 (± 3.21) | 3.47 (±3.32) | 0.469 | ||||